Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DMPHF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DMPHF and 80,000+ other tickers.
See exactly how DMPHF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DMPHF and 80,000+ other tickers.
Dermapharm Holding SE is an international pharmaceutical company specializing in off-patent branded medications, serving both domestic and global markets. Its business is structured across three distinct segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Imports, and Herbal Extracts. The company's comprehensive activities encompass the development, production, licensing, marketing, and distribution of its offerings. Its product range includes reputable generic drugs, non-prescription remedies, natural over-the-counter treatments, and a variety of other health products…
No recent news available.